Matrix metalloproteinases and tissue plasminogen activator reperfusion therapy for stroke

Handbook of Neurochemistry and Molecular Neurobiology: Acute Ischemic Injury and Repair in the Nervous System

Volumn , Issue , 2007, Pages 269-286

  Ning, M M ^a   Montaner, J ^a   Wang, X ^a   Lee, S R ^a   Tsuji, K ^a   Tejima, E ^a   Buchan, A M ^a   Lo, E H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900088211     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-30383-3_15     Document Type: Chapter

References (128)

1. Protocol for the multicenter acute stroke trial-thrombolysis study. Clin Trials Metaanal 28(6):329-344.
2. Abilleira S, Montaner J, Molina CA, Monasterio J, Castillo J, et al. 2003. Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. J Neurosurg 99(1):65-70.
3. Akassoglou K, Kombrinck KW, Degen JL, Strickland S. 2000. Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. J Cell Biol 149(5):1157-1166.
4. Albers GW, Clark WM, Madden KP, Hamilton SA. 2002. ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Stroke 33(2):493-495.
5. American Heart Association. Heart Disease and Stroke Statistics-2006 Update. Dallas, Texas: American Heart Association; 2006.
6. Andersen M, Overgaard K, Meden P, Boysen G, Choi SC. 1999. Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke 30(7):1464-1471.
7. Aoki T, Sumii T, Mori T, Wang X, Lo EH. 2002. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 33(11):2711-2717.
8. Asahi M, Wang X, Mori T, Sumii T, Jung JC, et al. 2001. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21(19):7724-7732.
9. Backstrom JR, Lim GP, Cullen MJ, Tokes ZA. 1996. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 16(24):7910-7919.
10. Baranes D, Lederfein D, Huang YY, Chen M, Bailey CH, et al. 1998. Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron 21(4):813-825.
11. Beck KF, Eberhardt W, Frank S, Huwiler A, Messmer UK, et al. 1999. Inducible NO synthase: role in cellular signalling. J Exp Biol 202(Pt. 6):645-653.
12. Bignami A, Cella G, Chi NH. 1982. Plasminogen activators in rat neural tissues during development and in Wallerian degeneration. Acta Neuropathol (Berl) 58(3):224-228.
13. Buchan AM, Warren DT. (2002). tPA toxicity in experimental cerebral ischemia: mechamnisms and clinical implications. In: Phamacology of cerebral ischemia (Krieglstein J, Klumpp S, eds), 193-199.
14. Bugge TH, Flick MJ, Daugherty CC, Degen JL. 1995. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 9(7):794-807.
15. Calabresi P, Napolitano M, Centonze D, Marfia GA, Gubellini P, et al. 2000. Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. Eur J Neurosci 12(3):1002-1012.
16. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, et al. 1994. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368(6470):419-424.
17. Carroll PM, Tsirka SE, Richards WG, Frohman MA, Strickland S. 1994. The mouse tissue plasminogen activator gene 5'0 flanking region directs appropriate expression in development and a seizure-enhanced response in the CNS. Development 120(11):3173-3183.
18. Carter LP, Guthkelch AN, Orozco J, Temeltas O. 1992. Influence of tissue plasminogen activator and heparin on cerebral ischemia in a rabbit model. Stroke 23(6):883-888.
19. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, et al. 2003. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 34(1):40-46.
20. Chan PH. 1996. Role of oxidants in ischemic brain damage. Stroke 27(6):1124-1129.
21. Chan PH. 2001. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 21(1):2-14.
22. Chen ZL, Strickland S. 1997. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 91(7):917-925.
23. Chen ZL, Yoshida S, Kato K, Momota Y, Suzuki J, et al. 1995. Expression and activity-dependent changes of a novel limbic-serine protease gene in the hippocampus. J Neurosci 15(7 Pt. 2):5088-5097.
24. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, et al. 1999. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282(21):2019-2026.
25. Davies BJ, Pickard BS, Steel M, Morris RG, Lathe R. 1998. Serine proteases in rodent hippocampus. J Biol Chem 273(36):23004-23011.
26. Donnan GA, Hommel M, Davis SM, McNeil JJ. 1995. Streptokinase in acute ischaemic stroke. Steering Committees of the ASK and MAST-E trials. Australian Streptokinase Trial. Lancet 346(8966):56.
27. Eberhardt W, Beck KF, Pfeilschifter J. 2002. Cytokine-induced expression of tPA is differentially modulated by NO and ROS in rat mesangial cells. Kidney Int 61(1):20-30.
28. Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161-174.
29. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, et al. 1998. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 50(4):883-890.
30. Fernandez-Monreal M, Lopez-Atalaya JP, Benchenane K, Leveille F, Cacquevel M, et al. 2004. Is tissue-type plasminogen activator a neuromodulator? Mol Cell Neurosci 25(4):594-601.
31. Frey U, Muller M, Kuhl D. 1996. A different form of longlasting potentiation revealed in tissue plasminogen activator mutant mice. J Neurosci 16(6):2057-2063.
32. Friedman GC, Seeds NW. 1995. Tissue plasminogen activator mRNA expression in granule neurons coincides with their migration in the developing cerebellum. J Comp Neurol 360(4):658-670.
33. Frisch SM, Francis H. 1994. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 124:619-626.
34. Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH. 2001. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 21(12):1393-1400.
35. Gautier S, Petrault O, Gele P, Laprais M, Bastide M, et al. 2003. Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function. Stroke 34(12):2975-2979.
36. Gingrich MB, Junge CE, Lyuboslavsky P, Traynelis SF. 2000. Potentiation of NMDA receptor function by the serine protease thrombin. J Neurosci 20(12):4582-4595.
37. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study. 1995. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333(24):1581-1587.
38. The NINDS Stroke Program Review. 2000. Report of the Stroke Progress Review Group, NINDS. 1-116.
39. Gschwend TP, Krueger SR, Kozlov SV, Wolfer DP, Sonderegger P. 1997. Neurotrypsin, a novel multidomain serine protease expressed in the nervous system. Mol Cell Neurosci 9(3):207-219.
40. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, et al. 2002. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297(5584):1186-1190.
41. Gualandris A, Jones TE, Strickland S, Tsirka SE. 1996. Membrane depolarization induces calcium-dependent secretion of tissue plasminogen activator. J Neurosci 16(7):2220-2225.
42. Hacke W, Bluhmki E, Steiner T, Tatlisumak T, Mahagne MH, et al. 1998a. Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I. Stroke 29(10):2073-2075.
43. Hacke W, Kaste M, Fieschi C, Von Kummer R, Davalos A, et al. 1998b. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352(9136):1245-1251.
44. Hacke W, Donnan G, Fieschi C, Kaste M, Von Kummer R, et al. 2004. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363(9411):768-774.
45. Hamann GF, Okada Y, Del Zoppo GJ. 1996. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab 16(6):1373-1378.
46. Hamann GF, Okada Y, Fitridge R, Del Zoppo GJ. 1995. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 26(11):2120-2126.
47. Hill MD, Buchan AM. 2001. Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). CASES Investigators. Can J Neurol Sci 28(3):232-238.
48. Hoffman KB, Larson J, Bahr BA, Lynch G. 1998. Activation of NMDA receptors stimulates extracellular proteolysis of cell adhesion molecules in hippocampus. Brain Res 811(1-2):152-155.
49. Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, et al. 1995. Termination of trial of streptokinase in severe acute ischaemic stroke. MAST Study Group. Lancet 345(8941):57.
50. Huang YY, Bach ME, Lipp HP, Zhuo M, Wolfer DP, et al. 1996. Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. Proc Natl Acad Sci USA 93(16):8699-8704.
51. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, et al. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 265(5180):1883-1885.
52. Justicia C, Panes J, Sole S, Cervera A, Deulofeu R, et al. 2003. Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab 23(12):1430-1440.
53. Kano T, Katayama Y, Tejima E, Lo EH. 2000. Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke. Brain Res 854(1-2):245-248.
54. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, et al. 2000. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 283(9):1151-1158.
55. Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM. 2004. The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab 24(9):945-963.
56. Kilic E, Bahr M, Hermann DM. 2001. Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations. Stroke 32(11):2641-2647.
57. Klein GM, Li H, Sun P, Buchan AM. 1999. Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia. Neurology 52(7):1381-1384.
58. Krystosek A, Seeds NW. 1981. Plasminogen activator release at the neuronal growth cone. Science 213(4515):1532-1534.
59. Krystosek A, Seeds NW. 1984. Peripheral neurons and Schwann cells secrete plasminogen activator. J Cell Biol 98(2):773-776.
60. Lapchak PA, Chapman DF, Zivin JA. 2000. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 31(12):3034-3040.
61. Lee SR, Lo EH. 2004. Induction of caspase-mediated cell death by matrix metalloproteinases in cerebral endothelial cells after hypoxia-reoxygenation. J Cereb Blood Flow Metab 24(7):720-727.
62. Lijnen HR. 2001. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 86(1):324-333.
63. Lo EH, Broderick JP, Moskowitz MA. 2004. tPA and proteolysis in the neurovascular unit. Stroke 35(2):354-356.
64. Lo EH, Dalkara T, Moskowitz MA. 2003. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4(5):399-415.
65. Lo EH, Wang X, Cuzner ML. 2002. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J Neurosci Res 69(1):1-9.
66. Lu W, Tsirka SE. 2002. Partial rescue of neural apoptosis in the Lurcher mutant mouse through elimination of tissue plasminogen activator. Development 129(8):2043-2050.
67. Madani R, Hulo S, Toni N, Madani H, Steimer T, et al. 1999. Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J 18(11):3007-3012.
68. Maier CM, Ahern K, Cheng ML, Lee JE, Yenari MA, et al. 1998. Optimal depth and duration of mild hypothermia in a focal model of transient cerebral ischemia: effects on neurologic outcome, infarct size, apoptosis, and inflammation. Stroke 29(10):2171-2180.
69. Maier CM, Hsieh L, Yu F, Bracci P, Chan PH. 2004. Matrix metalloproteinase-9 and myeloperoxidase expression: quantitative analysis by antigen immunohistochemistry in a model of transient focal cerebral ischemia. Stroke 35(5):1169-1174.
70. Mecenas PE, Tsirka SE, Salles F, Strickland S. 1997. Removal of tissue plasminogen activator does not protect against neuronal degeneration in the cerebellum of the weaver mouse. Brain Res 772(1-2):233-238.
71. Meng W, Wang X, Asahi M, Kano T, Asahi K, et al. 1999. Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J Cereb Blood Flow Metab 19(12):1316-1321.
72. Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, et al. 2001. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32(8):1759-1766.
73. Montaner J, Molina CA, Arenillas JF, Ribó M, Huertas R, et al. 2004. Proteolytic modifications on the metalloproteinase system (MMP-9-Laminin-TIMP-1) induced by t-PA treatment for acute cerebral ischemia in humans. Stroke 35:339.
74. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, et al. 2003. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107(4):598-603.
75. Mori T, Wang X, Aoki T, Lo EH. 2002. Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury. J Neurotrauma 19(11):1411-1419.
76. Mori T, Wang X, Kline AE, Siao CJ, Dixon CE, et al. 2001. Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma. Neuroreport 12(18):4117-4120.
77. Morita-Fujimura Y, Fujimura M, Gasche Y, Copin JC, Chan PH. 2000. Overexpression of copper and zinc superoxide dismutase in transgenic mice prevents the induction and activation of matrix metalloproteinases after cold injuryinduced brain trauma. J Cereb Blood Flow Metab 20(1):130-138.
78. Mun-Bryce S, Rosenberg GA. 1998. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 18(11):1163-1172.
79. Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ. 1992. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci 667:1-12.
80. Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. 1999a. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 99(18):2440-2444.
81. Nagai N, Vanlinthout I, Collen D. 1999b. Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models. Circulation 100(25):2541-2546.
82. Nagai N, Zhao BQ, Suzuki Y, Ihara H, Urano T, et al. 2002. Tissue-type plasminogen activator has paradoxical roles in focal cerebral ischemic injury by thrombotic middle cerebral artery occlusion with mild or severe photochemical damage in mice. J Cereb Blood Flow Metab 22(6):648-651.
83. Nagase H, Visse R, Murphy G. 2006. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res Feb. 15; 69(3):562-73.
84. Neuhoff H, Roeper J, Schweizer M. 1999. Activity-dependent formation of perforated synapses in cultured hippocampal neurons. Eur J Neurosci 11(12):4241-4250.
85. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, et al. 2001. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 7(1):59-64.
86. Ning MM, Lo EH, Furie KL, Koroshetz WJ, Sleeper L, et al. 2004. T-PA-mediated increase in matrix metalloproteinase-9 in acute ischemic stroke is independent of inflammatory response. Stroke 35(1):298.
87. Ning MM, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang XY, Zhu MW, Sorensen AG, Lo EH, Kelly PJ. 2006. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology (66):1550-1555.
88. Nishibori M, Ohtsuka A, Kawabata M, Nakaya N, Murakami T, et al. 1995. A novel serpin-like protein, B-43, exists in both neurons and astrocytes: an immunohistochemical study in the parietal region of the bovine brain. Neurosci Lett 200(2):125-128.
89. Opdenakker G, Van Den Steen PE, Dubois B, Nelissen I, Van Coillie E, et al. 2001. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 69(6):851-859.
90. Parmer RJ, Mahata M, Mahata S, Sebald MT, O'Connor DT, et al. 1997. Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA. J Biol Chem 272(3):1976-1982.
91. Pawlak R, Strickland S. 2002. Tissue plasminogen activator and seizures: a clot-buster's secret life. J Clin Invest 109(12):1529-1531.
92. Petty MA, Lo EH. 2002. Junctional complexes of the bloodbrain barrier: permeability changes in neuroinflammation. Prog Neurobiol 68(5):311-323.
93. Pfefferkorn T, Rosenberg GA. 2003. Closure of the bloodbrain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34(8):2025-2030.
94. Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. 1993. Tissue-plasminogen activator is induced as an immediateearly gene during seizure, kindling and long-term potentiation. Nature 361(6411):453-457.
95. Rogove AD, Siao C, Keyt B, Strickland S, Tsirka SE. 1999. Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. J Cell Sci 112(Pt. 22):4007-4016.
96. Rosenberg GA. 1995. Matrix metalloproteinases in brain injury. J Neurotrauma 12(5):833-842.
97. Rosenberg GA. 2002. Matrix metalloproteinases in neuroinflammation. Glia 39(3):279-291.
98. Rosenberg GA, Estrada EY, Dencoff JE. 1998. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29(10):2189-2195.
99. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, et al. 1992. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 576(2):203-207.
100. Rosenberg GA, Navratil M, Barone F, Feuerstein G. 1996. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 16(3):360-366.
101. Salles FJ, Strickland S. 2002. Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus. J Neurosci 22(6):2125-2134.
102. Sappino AP, Madani R, Huarte J, Belin D, Kiss JZ, et al. 1993. Extracellular proteolysis in the adult murine brain. J Clin Invest 92(2):679-685.
103. Scarisbrick IA, Isackson PJ, Ciric B, Windebank AJ, Rodriguez M. 2001. MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. J Comp Neurol 431(3):347-361.
104. Siao CJ, Tsirka SE. 2002. Extracellular proteases and neuronal cell death. Cell Mol Biol (Noisy-le-grand) 48(2):151-161.
105. Siao CJ, Fernandez SR, Tsirka SE. 2003. Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury. J Neurosci 23(8):3234-3242.
106. Siconolfi LB, Seeds NW. 2001. Mice lacking tPA, uPA, or plasminogen genes showed delayed functional recovery after sciatic nerve crush. J Neurosci 21(12):4348-4355.
107. Steiner T, Bluhmki E, Kaste M, Toni D, Trouillas P, et al. 1998. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study. Cerebrovasc Dis 8(4):198-203.
108. Sumii T, Lo EH. 2002. Involvement of matrix metalloproteinaseinthrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33(3):831-836.
109. Tabrizi P, Wang L, Seeds N, McComb JG, Yamada S, et al. 1999. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol 19(11):2801-2806.
110. Tanne D, Bates VE, Verro P, Kasner SE, Binder JR, et al. 1999. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology 53(2):424-427.
111. Tsirka SE, Gualandris A, Amaral DG, Strickland S. 1995. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377(6547):340-344.
112. Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. 1997. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 17(2):543-552.
113. Tsirka SE, Rogove AD, Strickland S. 1996. Neuronal cell death and tPA. Nature 384(6605):123-124.
114. Wang X, Lo EH. 2003. Triggers and mediators of hemorrhagic transformation in cerebral ischemia. Mol Neurobiol 28(3):229-244.
115. Wang X, Jung J, Asahi M, Chwang W, Russo L, et al. 2000. Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci 20(18):7037-7042.
116. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, et al. 2003. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9(10):1313-1317.
117. Wang X, Mori T, Jung JC, Fini ME, Lo EH. 2002. Secretion of matrix metalloproteinase-2 and -9 after mechanical trauma injury in rat cortical cultures and involvement of MAP kinase. J Neurotrauma 19(5):615-625.
118. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, et al. 2004. Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke. Stroke.
119. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, et al. 1998. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 4(2):228-231.
120. Warren DT, Klein G, Eliasziw M, Buchan AM. 2003. Neurotoxic Effects of t-PA in a rat model of permanent focal ischemia. Nuerology 60(Suppl. 1):A65.
121. Wu YP, Siao CJ, Lu W, Sung TC, Frohman MA, et al. 2000. The tissue plasminogen activator (tPA)/plasmin extracellular proteolytic system regulates seizure-induced hippocampal mossy fiber outgrowth through a proteoglycan substrate. J Cell Biol 148(6):1295-1304.
122. Yang Y, Li Q, Yang T, Hussain M, Shuaib A. 2003. Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101, 606-627 alone and in combination with rt-PA in a thromboembolic stroke model in rats. J Neurosurg 98(2):397-403.
123. Yenari MA, Palmer JT, Bracci PM, Steinberg GK. 1995. Thrombolysis with tissue plasminogen activator (tPA) is temperature dependent. Thromb Res 77(5):475-481.
124. Yepes M, Sandkvist M, Coleman TA, Moore E, Wu JY, et al. 2002. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest 109(12):1571-1578.
125. Yong VW, Power C, Forsyth P, Edwards DR. 2001. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2(7):502-511.
126. Zhang RL, Zhang L, Jiang Q, Zhang ZG, Goussev A, et al. 2000. Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat. Brain Res 878(1-2):64-71.
127. Zhao BQ, Ikeda Y, Ihara H, Urano T, Fan W, et al. 2004. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood 103(7):2610-2616.
128. Zhuo M, Holtzman DM, Li Y, Osaka H, De Maro J, et al. 2000. Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J Neurosci 20(2):542-549.